Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yun Fan

Showing results (881-890 of 920) with videos related to

Pageof 92
Sort By:
The Lancet. Respiratory Medicine|December 21, 2020
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trialCaicun Zhou, Gongyan Chen, Yunchao Huang, et al.
Lancet (London, England)|May 29, 2026
Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trialAnwen Xiong, Wenxiu Yao, Wei Zheng, et al.
Cancer Communications (London, England)|November 4, 2022
Multiplexed imaging of tumor immune microenvironmental markers in locally advanced or metastatic non-small-cell lung cancer characterizes the features of response to PD-1 blockade plus chemotherapyFengying Wu, Tao Jiang, Gongyan Chen, et al.
Cancer Communications (London, England)|October 26, 2021
Paclitaxel liposome for injection (Lipusu) plus cisplatin versus gemcitabine plus cisplatin in the first-line treatment of locally advanced or metastatic lung squamous cell carcinoma: A multicenter, randomized, open-label, parallel controlled clinical studyJie Zhang, Yueyin Pan, Qin Shi, et al.
The Lancet. Respiratory Medicine|October 20, 2019
Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trialYunpeng Yang, Jianya Zhou, Jianying Zhou, et al.
Cancer|November 13, 2019
Final report of a prospective randomized study on thoracic radiotherapy target volume for limited-stage small cell lung cancer with radiation dosimetric analysesXiao Hu, Yong Bao, Yu-Jin Xu, et al.
Eclinicalmedicine|May 27, 2024
Effects of sintilimab plus chemotherapy as first-line treatment on health-related quality of life in patients with advanced esophageal squamous cell carcinoma: results from the randomized phase 3 ORIENT-15 studyZhihao Lu, Li Kong, Buhai Wang, et al.
Journal of Critical Care|November 13, 2025
Nationwide expert survey on transfusion and coagulation management strategies for bleeding critically ill patients in ChinaSiying Chen, Lu Xu, Shiyu Liu, et al.
Military Medical Research|June 11, 2024
Genome-wide enhancer RNA profiling adds molecular links between genetic variation and human cancersYi-Min Cai, Ze-Qun Lu, Bin Li, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 6, 2022
Efficacy and Safety of Limertinib (ASK120067) in Patients With Locally Advanced or Metastatic EGFR Thr790Met-Mutated NSCLC: A Multicenter, Single-Arm, Phase 2b StudyYuankai Shi, Baolan Li, Lin Wu, et al.
Pageof 92

Showing results (881-890 of 920) with videos related to

Sort By:
Pageof 92
The Lancet. Respiratory Medicine|December 21, 2020
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trialCaicun Zhou, Gongyan Chen, Yunchao Huang, et al.
Lancet (London, England)|May 29, 2026
Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trialAnwen Xiong, Wenxiu Yao, Wei Zheng, et al.
Cancer Communications (London, England)|November 4, 2022
Multiplexed imaging of tumor immune microenvironmental markers in locally advanced or metastatic non-small-cell lung cancer characterizes the features of response to PD-1 blockade plus chemotherapyFengying Wu, Tao Jiang, Gongyan Chen, et al.
Cancer Communications (London, England)|October 26, 2021
Paclitaxel liposome for injection (Lipusu) plus cisplatin versus gemcitabine plus cisplatin in the first-line treatment of locally advanced or metastatic lung squamous cell carcinoma: A multicenter, randomized, open-label, parallel controlled clinical studyJie Zhang, Yueyin Pan, Qin Shi, et al.
The Lancet. Respiratory Medicine|October 20, 2019
Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trialYunpeng Yang, Jianya Zhou, Jianying Zhou, et al.
Cancer|November 13, 2019
Final report of a prospective randomized study on thoracic radiotherapy target volume for limited-stage small cell lung cancer with radiation dosimetric analysesXiao Hu, Yong Bao, Yu-Jin Xu, et al.
Eclinicalmedicine|May 27, 2024
Effects of sintilimab plus chemotherapy as first-line treatment on health-related quality of life in patients with advanced esophageal squamous cell carcinoma: results from the randomized phase 3 ORIENT-15 studyZhihao Lu, Li Kong, Buhai Wang, et al.
Journal of Critical Care|November 13, 2025
Nationwide expert survey on transfusion and coagulation management strategies for bleeding critically ill patients in ChinaSiying Chen, Lu Xu, Shiyu Liu, et al.
Military Medical Research|June 11, 2024
Genome-wide enhancer RNA profiling adds molecular links between genetic variation and human cancersYi-Min Cai, Ze-Qun Lu, Bin Li, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 6, 2022
Efficacy and Safety of Limertinib (ASK120067) in Patients With Locally Advanced or Metastatic EGFR Thr790Met-Mutated NSCLC: A Multicenter, Single-Arm, Phase 2b StudyYuankai Shi, Baolan Li, Lin Wu, et al.
Pageof 92